Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.74 |
| ▸ | PARP1 | P09874 | 6/20 | 0.74 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.69 |
| ▸ | GRM5 | P41594 | 5/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | FABP6 | P51161 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888691 | 0.89 | PARP10 (0.60) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL8167145 | 0.86 | PARP10 (0.76) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL8151102 | 0.86 | PARP10 (0.70) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL23952279 | 0.85 | PARP10 (1.00) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL29914810 | 0.85 | PARP10 (1.00) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL504325 | 0.82 | GRM5 (1.00) | PARP10PARP1PARP11GRM5 | |
| SCHEMBL8151110 | 0.82 | PARP10 (0.78) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL164795 | 0.81 | GRM5 (0.68) | PARP10PARP1PARP11GRM5FABP6 | |
| SCHEMBL30545957 | 0.81 | GRM5 (0.68) | PARP10PARP1PARP11GRM5FABP6 | |
| SCHEMBL5286063 | 0.80 | MAPK14 (0.62) | PARP10PARP1PARP11GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122055343-A | Deuterium and aryl amine compounds and uses thereof | 泽农医药公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12617811-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250154140-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | Sunnybrook Research Institute (CA) | 2025-05-15 | — | — | US | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007625-A2 | HETEROCYCLIC AMIDES WITH ANTI-TUBERCULOSIS ACTIVITY | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1252161-A1 | PYRROLO-ISOQUINOLINE AND TETRAHYDROPYRROLO-ISOQUINOLINE DERIVATIVES AND THEIR USE AS MEDIATORS OF THE 5-HT7 RECEPTOR | Wyeth (US) | 2002-10-30 | — | — | EP | disclosed |
| US-6432974-B1 | CIRCADIAN RHYTHYM, SLEEP, SEXUAL, NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS; DRUG ABUSE, DRUG DEPENDENCE, AND SCHIZOPHRENIA TREATMENT | WYETH | 2002-08-13 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-2001057039-A1 | PYRROLO-ISOQUINOLINE AND TETRAHYDROPYRROLO-ISOQUINOLINE DERIVATIVES AND THEIR USE AS MEDIATORS OF THE 5-HT7 RECEPTOR | WYETH (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | PARP10 810/4885PARP1 1017/4885PARP11 604/4885 |
| US-12617811-B2 | HPK1 inhibitors and uses thereof | MAP2K4, MAP2K1, MAP2K3 | PARP10 1083/4885PARP1 2349/4885PARP11 1218/4885 |
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | PARP10 3569/4885PARP1 4805/4885PARP11 4443/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PARP10 1131/4885PARP1 1728/4885PARP11 661/4885 |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | PARP10 4631/4885PARP1 4548/4885PARP11 4670/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PARP10 1131/4885PARP1 1728/4885PARP11 661/4885 |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI6, PADI2 | PARP10 291/4885PARP1 68/4885PARP11 186/4885 |
| US-20250154140-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | BAK1, BAX, BCL2 | PARP10 364/4885PARP1 122/4885PARP11 217/4885 |
| US-20050026968-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, HDAC5 | PARP10 3036/4885PARP1 4620/4885PARP11 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.